Views & Analysis | Perspectives on pharma industry issues

R&D

Digital pill, molecules inside, and digital hand with precision laser

Scientists and algorithms: Finding the right balance in mode...

The future of drug development is not scientists versus algorithms. It is scientists and algorithms working together.

Sales & Marketing

Sponsored

Local voices, global reach

Digital Opinion Leaders with regional followings are shaping prescribing behaviour in ways that international Key Opinion Leaders are not.

Sales & Marketing

Omnideployment concept, female hand holds digital globe and connected networks of men and women

Beyond omnichannel: Why pharma commercialisation must shift ...

We need to step away from the passive, broad concept of omnichannel and adopt a far more active, disciplined framework: omnideployment.

Digital

AI in clinical rials and drug development

AI in clinical trials: Building better trials before they st...

With AI, trial sponsors are now reducing risk, accelerating timelines, and driving innovation by modelling what is most likely to work in the future.

Digital

pharmaphorum podcast Episode 274, Erik Janssen, UCB

Sponsored

Ethical AI & trust-driven innovation: UCB’s Erik Janssen

How can pharma lead the way in ethical AI and trust-driven innovation?

Views & Analysis

Why blockchain is big pharma’s big focus

To address the supply chain vulnerabilities of the pharma industry, an innovative, collaborative blockchain-based system could help to keep track of drugs in transit and ensure they are sto

Sales & Marketing

Sponsored

Unlocking the full power of data for Pharma

The value of data has never been greater in healthcare.

Views & Analysis

How pharma can thrive in the digital era

December marks the one year anniversary of the U.S.

Sales & Marketing

Sponsored

Local voices, global reach

Digital Opinion Leaders with regional followings are shaping prescribing behaviour in ways that international Key Opinion Leaders are not.

Sales & Marketing

Beyond omnichannel: Why pharma commercialisation must shift ...

We need to step away from the passive, broad concept of omnichannel and adopt a far more active, disciplined framework: omnideployment.

Digital

AI in clinical trials: Building better trials before they st...

With AI, trial sponsors are now reducing risk, accelerating timelines, and driving innovation by modelling what is most likely to work in the future.

Digital

Sponsored

Ethical AI & trust-driven innovation: UCB’s Erik Janssen

How can pharma lead the way in ethical AI and trust-driven innovation?

Market Access

The EU Joint Clinical Assessment in practice: Early lessons

Unfortunately, much of the discussion around the JCA has focused on how the framework is intended to operate, rather than how it works in practice.

Market Access

Navigating Europe's AI regulatory labyrinth: A strategic gui...

For US drug developers, bringing AI tools across the Atlantic introduces steep regulatory hurdles.

Oncology

Bridging the innovation gap: Scalable cell therapies, adapti...

Biotech must build manufacturing and trial models that make cell therapies scalable, accessible & commercially viable.

Oncology

Building a Phase I oncology centre

The question is not whether an institution should ultimately develop Phase Ia capability. It is when the organisation is ready.

Oncology

Key lessons from EHA 2026: Translating evidence into impact

Across four days in Sweden, EHA 2026 offered a clear view of the future of blood cancer care.

Patients

Woman in yellow jacket blows nose due to hayfever

Redefining the self-care pathway in the evolving hayfever la...

When it comes to hayfever, proactive approach improves patient health literacy and empowers individuals to put their health back in their own hands.

Patients

Pharmacist hands woman prescription medicine with an explanation

Specialty medication access hinges on a 48-hour window

The vast majority of healthcare providers (HCPs) say that PA-related delays directly harm patient outcomes.

Patients

Man lies on floor next to spilled pill bottle, reference to overdose

Decline in overdose deaths ≠ The end of the opioid crisis

Since 2001, International Overdose Day has been observed as a moment to remember those lost to overdose and renew society’s commitment to

Scientists and algorithms: Finding the right balance in mode...

Local voices, global reach

Beyond omnichannel: Why pharma commercialisation must shift ...

AI in clinical trials: Building better trials before they st...

Ethical AI & trust-driven innovation: UCB’s Erik Janssen

Why blockchain is big pharma’s big focus

Unlocking the full power of data for Pharma

How pharma can thrive in the digital era

Local voices, global reach

Beyond omnichannel: Why pharma commercialisation must shift ...

AI in clinical trials: Building better trials before they st...

Ethical AI & trust-driven innovation: UCB’s Erik Janssen

The EU Joint Clinical Assessment in practice: Early lessons

Navigating Europe's AI regulatory labyrinth: A strategic gui...

Bridging the innovation gap: Scalable cell therapies, adapti...

Building a Phase I oncology centre

Key lessons from EHA 2026: Translating evidence into impact

Redefining the self-care pathway in the evolving hayfever la...

Specialty medication access hinges on a 48-hour window

Decline in overdose deaths ≠ The end of the opioid crisis

Scientists and algorithms: Finding the right balance in mode...

Back to basics: X-ray inspection in pharmaceutical and medic...

Decarbonising respiratory care requires a new kind of generi...

Amgen's Imdelltra scores again in small cell lung cancer

Discover a new era of healthcare panel engagement: Grounded ...

Sales & Marketing

Digital

Market Access

Editor's Picks

Oncology

Patients

R&D

Editor's Picks